Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hematide vs rhTPO to prevent delayed platelet recovery after allo-HSCT
ChiCTR2400094378Phase 4Recruiting
- Sponsor
- Guangdong Provincial Hosipital of Chinese Medicine
- Start
- Dec 2024
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Peptides, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised trial in hematopoietic malignancies and Thrombocytopenia comparing Hematide group with rhTPO group (2 arms). Primary endpoint: Platelet implantation rate. Started Dec 2024; status: recruiting.
02
Drugs
peginesatiderecombinant human thrombopoietin
03
Conditions
hematopoietic malignanciesThrombocytopenia
Beyond the preview
Go deeper on ChiCTR2400094378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094378.